March 06, 2026 — Princeton, New Jersey, USA
A major milestone in the treatment of autoimmune diseases has been reached as Bristol Myers Squibb announced that the U.S. Food and Drug Administration has approved Sotyktu for the treatment of adults with active psoriatic arthritis (PsA). The once-daily oral therapy represents the first and only tyrosine kinase 2 (TYK2) inhibitor approved for this indication, marking a significant advancement in targeted therapies designed to address both joint inflammation and skin symptoms associated with psoriatic disease. The regulatory decision follows strong clinical evidence demonstrating that patients treated with Sotyktu experienced significantly higher clinical response rates compared with placebo, reinforcing the drug’s potential role as a new treatment option for individuals living with this chronic inflammatory condition.
Phase 3 Clinical Trials Demonstrate Significant Patient Benefits
The FDA approval is based on positive results from the Phase 3 POETYK PsA-1 and POETYK PsA-2 clinical trials, two large multicenter studies designed to evaluate the efficacy and safety of Sotyktu in adults with active psoriatic arthritis. These randomized, double-blind, placebo-controlled trials involved more than 1,200 patients, including individuals who had not previously received biologic disease-modifying antirheumatic drugs as well as those who had prior exposure to TNF-alpha inhibitors.
Results from the trials demonstrated that Sotyktu significantly improved disease activity compared with placebo, achieving higher rates of ACR20 responses at Week 16, which represents at least a 20 percent improvement in symptoms based on American College of Rheumatology criteria. In the PsA-1 trial, 54 percent of patients treated with Sotyktu achieved ACR20 response compared with 34 percent of patients receiving placebo, while the PsA-2 trial also reported 54 percent response in the Sotyktu group versus 39 percent for placebo. Additional clinical endpoints including ACR50, ACR70, and minimal disease activity responses further confirmed the drug’s therapeutic benefit.
Beyond joint symptom improvement, patients receiving Sotyktu also experienced improvements in quality of life and physical functioning, as measured through validated patient-reported outcome tools such as the 36-Item Short Form Health Survey (SF-36). Improvements were observed across key domains including physical functioning, pain reduction, and overall health perception, highlighting the therapy’s potential to significantly improve daily life for individuals suffering from psoriatic arthritis.
Advertisement
First TYK2 Inhibitor Approved for Psoriatic Arthritis
Sotyktu is a selective tyrosine kinase 2 (TYK2) inhibitor, designed to target specific immune signaling pathways involved in inflammatory and autoimmune diseases. The therapy works by blocking TYK2-mediated signaling of cytokines such as interleukin-23, interleukin-12, and type-1 interferons, which play an important role in the development and progression of psoriasis and psoriatic arthritis.
Unlike traditional Janus kinase (JAK) inhibitors, Sotyktu binds selectively to the regulatory domain of the TYK2 enzyme, producing a highly targeted allosteric inhibition mechanism. This selective approach allows the drug to modulate inflammatory pathways without significantly inhibiting related JAK family enzymes, potentially contributing to its favorable safety and tolerability profile observed in clinical trials.
The approval also expands the clinical role of Sotyktu, which was previously approved in 2022 for the treatment of adults with moderate-to-severe plaque psoriasis who are candidates for systemic therapy or phototherapy. Since its initial approval, the therapy has accumulated multiple years of clinical efficacy and safety data, strengthening its position as a key innovation within the immunology and dermatology treatment landscape.
Addressing Unmet Needs in Psoriatic Arthritis Treatment
Psoriatic arthritis is a chronic immune-mediated disease that affects both joints and skin, often causing pain, swelling, stiffness, and reduced mobility. The condition affects up to 30 percent of patients living with psoriasis and can lead to long-term joint damage if not effectively managed. Despite advances in biologic therapies, many patients still require additional treatment options that offer convenient administration and improved disease control.
As an oral once-daily therapy, Sotyktu offers a convenient alternative to injectable or infusion-based biologic treatments, potentially expanding treatment accessibility for patients seeking effective disease management. By addressing both joint inflammation and skin manifestations of psoriatic disease, the therapy represents a significant step forward in improving long-term clinical outcomes and quality of life for patients living with this complex autoimmune condition.
The latest regulatory approval further highlights Bristol Myers Squibb’s commitment to developing innovative immunology therapies aimed at addressing unmet medical needs across autoimmune and inflammatory diseases. As research continues to explore new applications for TYK2 inhibition, Sotyktu may play an increasingly important role in the evolving landscape of precision immunology treatments designed to deliver targeted, patient-focused care.
z
Source: Bristol Myers Squibb press release
